Eupraxia Pharmaceuticals
EPRX
67 hedge funds and large institutions have $164M invested in Eupraxia Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 22 increasing their positions, 17 reducing their positions, and 6 closing their positions.
200% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 6
29% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 17
22% more funds holding
Funds holding: 55 → 67 (+12)
1.35% more ownership
Funds ownership: 36.79% → 38.14% (+1.4%)
3% more capital invested
Capital invested by funds: $158M → $164M (+$5.31M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$4.62M |
| 2 |
Millennium Management
New York
|
+$3.04M |
| 3 |
PMAM
Picton Mahoney Asset Management
Toronto,
Ontario, Canada
|
+$2.49M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$2.11M |
| 5 |
Jane Street
New York
|
+$2.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Squadron Capital Management
Westmont,
Illinois
|
-$4.92M |
| 2 |
ABG
Ally Bridge Group
New York
|
-$2.81M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$2.79M |
| 4 |
DT
DV Trading
Chicago,
Illinois
|
-$2M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$1.68M |
EPRX Hedge Fund Activity: Q2 2026 in Review
67 of the 8,339 institutional investors tracked by Wall St. Rank reported a position in Eupraxia Pharmaceuticals (EPRX) for Q2 2026, worth a combined $164M — up 3.4% from $158M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new EPRX positions and 6 closed out — a net gain of 12 holders — while 22 added to existing stakes and 17 trimmed.
The largest buyer was PFM Health Sciences, adding an estimated $4.62M. The largest seller was Squadron Capital Management, exiting entirely with an estimated $4.92M sold.
- 67 institutional investors held Eupraxia Pharmaceuticals (EPRX) as of Q2 2026, up from 55 in Q1 2026.
- Funds reported $164M of Eupraxia Pharmaceuticals stock for Q2 2026, up 3.4% quarter-over-quarter.
- 18 funds opened new Eupraxia Pharmaceuticals positions in Q2 2026 and 6 closed out, a net change of +12 holders.
- The largest Eupraxia Pharmaceuticals buyer in Q2 2026 was PFM Health Sciences, an estimated $4.62M added.
- The largest Eupraxia Pharmaceuticals seller in Q2 2026 was Squadron Capital Management, an estimated $4.92M sold.
Based on aggregated 13F filings for Q2 2026.